In the long contest between HIV-1 and the human immune system, science has uncovered another hidden front: a cell-surface protein called ADAM17, long associated with inflammation, turns out to be a formidable gatekeeper against viral infection. Researchers have shown that ADAM17 physically traps the virus's envelope precursor inside the cell, preventing new infectious particles from forming — and that HIV's Nef protein has evolved a precise molecular strategy to evict this guardian. The discovery not only fills a longstanding gap in our understanding of how HIV sustains itself in the body, but
Scientists identify ADAM17 as major HIV restriction factor, revealing how Nef overcomes it
Nef redirects ADAM17 out of the cell, removing the obstacle to viral maturity
Mark
So ADAM17 is a protein that normally does something with inflammation, and now it turns out it also blocks HIV. How does that even happen?
Mimi
It's actually elegant. ADAM17 has a signal peptide—basically a molecular address tag—that normally helps direct proteins through the cell's secretory system. But it turns out this same peptide can grab onto HIV's envelope precursor, gp160, and trap it inside the endoplasmic reticulum. The virus can't mature if the envelope protein is stuck inside the cell.
Luke
Wait, so ADAM17 isn't using its enzymatic function at all? It's just physically holding the envelope protein hostage?
Mimi
Exactly. That's what makes it different from what we thought we knew. SERINC5, the other restriction factor, works through a different mechanism. But ADAM17 is just a physical barrier—it binds gp160 and keeps it from getting to the surface.
Mark
And HIV's Nef protein has figured out how to get around this?
Mimi
Yes. Nef has a PxxP motif that acts like a grappling hook. It uses that to redirect ADAM17 out of the cell, packaging it into extracellular vesicles that the cell naturally sheds. With less ADAM17 inside the cell, gp160 can mature and the virus can form.
Luke
So Nef is essentially removing the obstacle. But how confident are we that this is the main mechanism? Did they test this in actual infected cells?
Mimi
They disrupted ADAM17 in both T-cell lines and primary human lymphocytes. When ADAM17 was gone, the virus needed Nef much less. That's pretty strong evidence.
Luke
That's the key experiment, yes. But I'd want to know whether there are other restriction factors we haven't found yet. ADAM17 is clearly important, but is it the whole story?
Mark
What would that mean for treatment?
Mimi
If you could block Nef's ability to redirect ADAM17, you might be able to keep the restriction factor active even when Nef is present. That could make the virus less infectious.
Luke
That's the hypothesis. But we're still at the stage of understanding the mechanism. Turning that into a drug is several steps away.
The Pulse
- For decades, HIV's Nef protein was known to boost infectivity, but the specific cellular defense it was dismantling remained frustratingly incomplete — SERINC5 alone could not explain the full picture.
- ADAM17 has now been identified as a second major restriction factor, one that physically sequesters HIV's envelope precursor gp160 inside the endoplasmic reticulum, halting viral maturation without any enzymatic action.
- HIV fights back through Nef's PxxP motif, which hijacks the cell's own trafficking machinery to expel ADAM17 into extracellular vesicles, draining the cell of this defense and allowing the virus to complete its life cycle.
- Experiments in CD4-positive T-cell lines and primary human lymphocytes confirmed that removing ADAM17 sharply reduced the virus's dependence on Nef, identifying it as a critical — not redundant — bottleneck in viral replication.
- The findings open a therapeutic corridor: disrupting Nef's ability to redirect ADAM17, or engineering ADAM17 to resist that manipulation, could restore a natural antiviral brake even in active infections.
In the long contest between HIV-1 and the human immune system, science has uncovered another hidden front: a cell-surface protein called ADAM17, long associated with inflammation, turns out to be a formidable gatekeeper against viral infection. Researchers have shown that ADAM17 physically traps the virus's envelope precursor inside the cell, preventing new infectious particles from forming — and that HIV's Nef protein has evolved a precise molecular strategy to evict this guardian. The discovery not only fills a longstanding gap in our understanding of how HIV sustains itself in the body, but points toward a new class of therapeutic possibilities rooted in the ancient struggle between pathogen and host.
For years, researchers knew that HIV-1's small protein Nef was essential for making new virus particles highly infectious, yet the precise cellular defenses it was neutralizing remained only partially understood. SERINC5, a membrane protein, accounted for some of Nef's activity against laboratory strains — but not enough to explain the virus's success in real-world infections. A new study now identifies ADAM17 as a second, major restriction factor, filling a critical gap in the molecular story of HIV and its host.
ADAM17 is best known for its role in inflammation, where it cleaves signaling molecules on cell surfaces. The new research reveals an entirely different function: the protein intercepts HIV's envelope precursor, gp160, and holds it captive inside the endoplasmic reticulum, the cellular compartment where proteins are built and sorted. Trapped there, gp160 cannot mature, cannot reach the cell surface, and cannot be packaged into new viral particles — collapsing infectivity dramatically. Remarkably, ADAM17 achieves this not through its enzymatic activity but through its signal peptide, which binds directly to gp160 in a straightforward physical interaction. The restriction operates against both laboratory-adapted strains and primary isolates from infected patients, suggesting it represents genuine evolutionary pressure on the virus.
HIV's answer to this defense is Nef. Using a short protein-interaction sequence called a PxxP motif, Nef commandeers the cell's own trafficking machinery and forces ADAM17 out of the cell into extracellular vesicles — tiny membrane-bound packages that cells naturally shed. With ADAM17 depleted from the intracellular environment, gp160 is free to mature, viral particles can assemble, and infectivity is restored.
To validate the mechanism, researchers deleted the ADAM17 gene in CD4-positive T-cell lines and in primary human lymphocytes from donors. In both cases, the virus's reliance on Nef dropped substantially — confirming that ADAM17 is not one of many interchangeable defenses but a specific, major bottleneck that Nef has evolved to overcome. The discovery suggests a potential therapeutic angle: if Nef's ability to redirect ADAM17 could be blocked, or if ADAM17 could be made resistant to that manipulation, it might be possible to restore this natural antiviral brake even in the presence of an active infection — effectively disarming one of HIV's most critical evasion strategies.
For decades, researchers have watched HIV-1 deploy a small protein called Nef to make newly formed virus particles more infectious. What remained unclear was exactly which cellular defenses Nef was overriding. Scientists knew about SERINC5, a membrane protein that blocks certain laboratory strains of HIV, but this mechanism seemed incomplete—it didn't fully explain how the virus evaded the body's natural barriers in real-world infections. A team of researchers has now identified a second major player in this molecular standoff: ADAM17, a cell-surface protein that acts as a surprisingly effective HIV restriction factor.
ADAM17 is best known for its role in inflammation, where it cleaves signaling molecules on cell surfaces. But the new research reveals an entirely different function. The protein intercepts HIV's envelope precursor, gp160, and traps it inside the endoplasmic reticulum—the cellular compartment where proteins are manufactured and processed. By holding gp160 hostage in this internal space, ADAM17 prevents the envelope protein from maturing, traveling to the cell surface, and being packaged into new virus particles. The result is a dramatic reduction in viral infectivity. Crucially, this restriction works against both laboratory-adapted HIV strains and primary isolates taken directly from infected patients, suggesting it represents a genuine evolutionary pressure the virus must overcome.
What makes this discovery particularly striking is that ADAM17 accomplishes this feat without using its enzymatic machinery at all. Instead, its signal peptide—the molecular address tag that normally directs proteins into the secretory pathway—acts as a physical trap, binding directly to gp160 and holding it in place. This is not a chemical reaction but a straightforward molecular interaction, one that the virus has evolved a specific countermeasure to defeat.
That countermeasure is Nef. The viral protein contains a PxxP motif, a short sequence that serves as a protein-interaction handle. Nef uses this motif to hijack the cell's trafficking machinery, forcing ADAM17 out of the cell and into extracellular vesicles—tiny membrane-bound packages that cells naturally shed. By redirecting ADAM17 away from the endoplasmic reticulum and out of the cell entirely, Nef reduces the amount of the restriction factor available to trap gp160. With fewer ADAM17 molecules present, envelope maturation can proceed, viral particles can form, and infectivity is restored.
To confirm this mechanism, researchers disrupted the ADAM17 gene in CD4-positive T-cell lines—the primary target of HIV infection—and in primary human lymphocytes taken directly from donors. When ADAM17 was removed, the virus's dependence on Nef diminished substantially. This finding suggests that ADAM17 is not merely one of many redundant defenses but a major bottleneck that Nef has evolved specifically to overcome. The discovery opens a new angle on how the virus maintains its infectivity and, more importantly, hints at a potential therapeutic vulnerability. If ADAM17 can be manipulated or its interaction with gp160 disrupted, it might be possible to restore this restriction even in the presence of Nef, effectively disarming one of the virus's most critical evasion strategies.
The work represents a significant step forward in understanding the molecular choreography between HIV and its host. For years, the field has known that Nef is essential for viral replication in natural infections, yet the precise mechanisms remained fragmented. By identifying ADAM17 as a major restriction factor and mapping exactly how Nef overcomes it, researchers have filled a crucial gap in the picture. The next phase will likely focus on whether this interaction can be therapeutically exploited—whether blocking Nef's ability to redirect ADAM17 could render the virus less infectious, or whether ADAM17 itself could be engineered to resist Nef's manipulation.
Notable Quotes
ADAM17 acts independently of its enzymatic activity; its signal peptide binds the HIV-1 envelope precursor and retains it in the endoplasmic reticulum— Research findings
Want the full story?
Read the original at Nature ↗
Crime & Justice